Cat. No.: HY-15989

SM-164

55 Cited Publications

Avis client

Based on 55 publication(s) in Google Scholar

SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC₅₀ value of 1.39 nM and functions as an extremely potent antagonist of XIAP.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.53%
CAS No.: 957135-43-2
Formule: C₆₂H₈₄N₁₄O₆
Masse moléculaire:1121.42

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

SM-164 Chemical Structure

CAS No.: 957135-43-2

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (55)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]^[2]

cIAP-1

0.31 nM (Ki)

cIAP-2

1.1 nM (Ki)

cIAP

Voir tous les produits spécifiques à Isoform IAP :

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	IC₅₀	0.039 μM Compound: 7, SM-164	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23062821]
MDA-MB-231	IC₅₀	3.3 nM Compound: 16, SM-164	Growth inhibition of human MDA-MB-231 cells after 2 to 3 hrs by WST8 assay Growth inhibition of human MDA-MB-231 cells after 2 to 3 hrs by WST8 assay	[PMID: 21462933]
MDA-MB-231	IC₅₀	6.8 nM Compound: 6, SM-164	Growth inhibition of human MDA-MB-231 cells after 4 days by WST8 assay Growth inhibition of human MDA-MB-231 cells after 4 days by WST8 assay	[PMID: 22148838]
SK-OV-3	IC₅₀	16 nM Compound: 6, SM-164	Growth inhibition of human SKOV3 cells after 4 days by WST8 assay Growth inhibition of human SKOV3 cells after 4 days by WST8 assay	[PMID: 22148838]

In Vitro

SM-164 is a non-peptide, cell-permeable, bivalent small-molecule, which mimics Smac protein for targeting XIAP. SM-164 binds to XIAP containing both BIR domains with an IC₅₀ value of 1.39 nM, being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively. SM-164 concurrently interacts with both BIR domains in XIAP and functions as an ultra-potent antagonist of XIAP in both cell-free functional and cell-based assays. SM-164 targets cellular XIAP and effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells, while having a minimal toxicity to normal human primary cells at 10,000 nM^[1]. The binding affinities of SM-164 to XIAP, cIAP-1, and cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 has a K_i value of 0.56 nM to XIAP protein containing both BIR2 and BIR3 domains. SM-164 has a K_i value of 0.31 nM to cIAP-1 protein containing both BIR2 and BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with K_i values of 1.1 nM. Addition of exogenous TNFα can significantly enhance the activity of these Smac mimetics, especially for SM-164, in resistant cancer cell lines such as HCT116 and MDA-MB-453^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SM-164 is evaluated for its ability to inhibit tumor growth. SM-164 is highly effective in inhibition of tumor growth and capable of achieving tumor regression in the MDA-MB-231 xenograft model. Treatment with SM-164 at 1 mg/kg completely inhibits tumor growth during the treatment. Treatment with SM-164 at 5 mg/kg reduces the tumor volume from 147±54 mm³ at the beginning of the treatment (day 25) to 54±32 mm³ at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long lasting and not transient. SM-164 at 5 mg/kg is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reached 750 mm³ (P<0.02)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 957135-43-2
Appearance Solid
Masse moléculaire 1121.42
Formule C₆₂H₈₄N₁₄O₆
Color White to light yellow
SMILES

C[C@H](NC)C(N[C@H]1CCCC[C@](CC[C@H]2C(N[C@@H](C3=CC=CC=C3)C4=CN(CCCCC5=CC=C(CCCCN6N=NC([C@@H](NC([C@@H]7CC[C@@](CCCC[C@@H]8NC([C@@H](NC)C)=O)([H])N7C8=O)=O)C9=CC=CC=C9)=C6)C=C5)N=N4)=O)([H])N2C1=O)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (55)

All WBCell Imaging/Staining

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. [Abstract]

2020 Oct 9;5(1):235. PMID: 33037188
Nature

Necroptosis blockade prevents lung injury in severe influenza. [Abstract]

2024 Apr;628(8009):835-843. PMID: 38600381
Cancer Cell

Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. [Abstract]

2025 May 12;43(5):955-969.e10. PMID: 40054466
Cell

Innate immune and metabolic signals induce mitochondria-dependent membrane lysis via mitoxyperiosis. [Abstract]

2025 Dec 11;188(25):7155-7174.e25. PMID: 41317732
Cell Res

Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate. [Abstract]

2023 Nov;33(11):835-850. PMID: 37726403
Mol Cell

Species-specific cleavage of the autophagy adaptor p62 dictates responses to TNF. [Abstract]

2026 Apr 16;86(8):1574-1586.e11. PMID: 41950919
Sci Immunol

Initiator cell death event induced by SARS-CoV-2 in the human airway epithelium. [Abstract]

2024 Jul 12;9(97):eadn0178. PMID: 38996010
Nat Commun

RIPK1 kinase drove brain microvascular endothelial cells death and blood-brain barrier disruption in neonatal Escherichia coli meningitis. [Abstract]

2025 Aug 7;16(1):7309. PMID: 40774959
Cell Death Dis

RIPK3 promotes skin inflammation by enhancing IL-36α signaling and necroptosis in keratinocytes. [Abstract]

2025 Oct 24;16(1):759. PMID: 41136377
Cell Death Dis

Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis. [Abstract]

2025 Jun 17;16(1):452. PMID: 40523886

SM-164 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jun 17;16(1):452. [Abstract]

Immunoblot analysis of cleaved PARP, cleaved caspase-3, GSDME, and cleaved GSDME in the indicated cells treated with RG7388 (15 μM), SM-164 (25-50 nM), or the combination of RG7388 and SM-164 for 6 or 24 h.

SM-164 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jun 17;16(1):452. [Abstract]

Bright-field microscopic images of TP53^mutant NSCLC organoids treated with RG7388 (15 μM), SM-164 (25 nM), or the combination of RG7388 and SM-164 for 24 h were shown.
Cell Death Dis

NLRP10 maintains epidermal homeostasis by promoting keratinocyte survival and P63-dependent differentiation and barrier function. [Abstract]

2024 Oct 18;15(10):759. PMID: 39424623
Cell Death Dis

c-Jun N-terminal kinases differentially regulate TNF- and TLRs-mediated necroptosis through their kinase-dependent and -independent activities. [Abstract]

2018 Nov 15;9(12):1140. PMID: 30442927

SM-164 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Nov 15;9(12):1140. [Abstract]

MEF cells are transfected with indicated siRNA for 3 days and then treated with TNF+Smac+zVAD, or poly I:C+zVAD for 3 h.
Proc Natl Acad Sci U S A

Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy. [Abstract]

2022 Sep 6;119(36):e2117396119. PMID: 36037337
Int J Biol Macromol

Polysaccharide from Strongylocentrotus nudus eggs regulates intestinal epithelial autophagy through CD36/PI3K-Akt pathway to ameliorate inflammatory bowel disease. [Abstract]

2023 Jul 31:244:125373. PMID: 37327932
Cell Death Discov

RIPK1 S213E mutant suppresses RIPK1-dependent cell death by preventing interactions with RIPK3 and CASP8. [Abstract]

2025 Jul 25;11(1):345. PMID: 40715038
Cell Death Discov

RIPK1 inhibitor ameliorates pulmonary injury by modulating the function of neutrophils and vascular endothelial cells. [Abstract]

2024 Mar 23;10(1):152. PMID: 38521771
Cell Rep

TCF25 serves as a nutrient sensor to orchestrate metabolic adaptation and cell death by enhancing lysosomal acidification under glucose starvation. [Abstract]

2025 Aug 21;44(9):116186. PMID: 40844875
J Med Chem

Development and Preclinical Evaluation of Novel F-18-Labeled Dihydropyrazole RIPK1 PET Tracers for Neuroinflammation Imaging. [Abstract]

2025 Dec 11;68(23):25590-25606. PMID: 41266996
J Med Chem

Bardoxolone Derivatives as Novel Pseudo-Natural Necroptosis Inhibitors by Destabilizing HSP90 Client Proteins. [Abstract]

2025 Apr 30. PMID: 40307003
J Med Chem

Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway. [Abstract]

2023 Apr 13;66(7):5261-5278. PMID: 36908007
J Med Chem

Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets. [Abstract]

2023 Feb 23;66(4):3073-3087. PMID: 36724216
J Med Chem

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease. [Abstract]

2022 Nov 10;65(21):14957-14969. PMID: 36288088
Oncoimmunology

Smad7 is a negative regulator of immunogenic cell death in colorectal cancer. [Abstract]

2025 Dec;14(1):2490346. PMID: 40213961
JCI Insight

SPOP mediates apoptosis and protects against necroptosis by regulating ubiquitination of RIPK1 and RIPK3. [Abstract]

2025 Oct 22;10(20):e180655. PMID: 41122967
Biomater Adv

Etoposide-loaded lipopolymer nanoparticles promote Smac minetic activity against inhibitor of apoptosis protein for glioblastoma treatment. [Abstract]

2025 Jan 13:170:214185. PMID: 39879864
Biomater Adv

Enhanced activity of AZD5582 and SM-164 in rabies virus glycoprotein-lactoferrin-liposomes to downregulate inhibitors of apoptosis proteins in glioblastoma. [Abstract]

2022 Feb:133:112615. PMID: 35525732
Eur J Med Chem

Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy. [Abstract]

2024 Apr 5:269:116304. PMID: 38484677
Eur J Med Chem

Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors. [Abstract]

2022 Jun 5;236:114345. PMID: 35398729
Eur J Med Chem

Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors. [Abstract]

2021 Aug 5:220:113484. PMID: 33930803
Biochem Pharmacol

Cabozantinib inhibits necroptosis by targeting MLKL oligomerization and alleviates psoriasis in vivo. [Abstract]

2026 Jun:248:117843. PMID: 41747872
J Ethnopharmacol

The traditional herb Sargentodoxa cuneata alleviates DSS-induced colitis by attenuating epithelial barrier damage via blocking necroptotic signaling. [Abstract]

2024 Jan 30;319(Pt 3):117373. PMID: 37923253
PLoS Pathog

RVFV virulence factor NSs triggers the mitochondrial MCL-1-BAK axis to activate pathogenic NLRP3 pyroptosis. [Abstract]

2024 Aug 30;20(8):e1012387. PMID: 39213434
Bioorg Chem

Identification of RIPK3 as a target of flavonoids for anti-necroptosis in vitro. [Abstract]

2025 Jul 1:161:108503. PMID: 40328155
Bioorg Chem

Discovery of novel 5-phenylpyrazol receptor interacting protein 1(RIP1) kinase inhibitors as anti-necroptosis agents by combining virtual screening and in vitro and in vivo experimental evaluations. [Abstract]

2024 Jan:142:106964. PMID: 37976678
Bioorg Chem

Analysis on benzothiazole necroptosis inhibitors with chiral substitutions in the solvent-accessible region of RIP kinase domain. [Abstract]

2023 Aug:137:106647. PMID: 37270986
Bioorg Chem

Profiling of the chemical space on the phenyl group of substituted benzothiazole RIPK3 inhibitors. [Abstract]

2023 Feb:131:106339. PMID: 36599218
Rheumatology (Oxford)

IAPs antagonist SM164 ameliorates experimental MPO-ANCA-associated vasculitis via enhancing fatty acid oxidation in neutrophils. [Abstract]

2023 Jul 5;62(7):2563-2573. PMID: 36308438
Mol Neurobiol

Inhibition of Neural Stem Cell Necroptosis Mediated by RIPK1/MLKL Promotes Functional Recovery After SCI. [Abstract]

2023 Apr;60(4):2135-2149. PMID: 36602703
J Cell Mol Med

Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1-mediated inflammatory signalling. [Abstract]

2024 Mar;28(5):e17929. PMID: 37643315
J Inflamm Res

Cell Death-Related Genesets Activity Improved Clinical Concordance and Intrinsically Associated with Alterations in Ulcerative Colitis: Mucosal Healing at Molecular Depth. [Abstract]

2025 Jul 19:18:9587-9608. PMID: 40708727
Mol Med Rep

Pristimerin ameliorates colitis‑induced intestinal mucosal injury by inhibiting intestinal epithelial necroptosis. [Abstract]

2025 Jun;31(6):153. PMID: 40211716
Bioorg Med Chem

Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors. [Abstract]

2024 Mar 15:102:117659. PMID: 38442525
Bioorg Med Chem

Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors. [Abstract]

2024 Feb 15:100:117611. PMID: 38309200
Bioorg Med Chem

Scaffold hopping derived novel benzoxazepinone RIPK1 inhibitors as anti-necroptosis agents. [Abstract]

2023 Aug 15:91:117385. PMID: 37364415
Biomed Res Int

Close Relationship between cIAP2 and Human ARDS Induced by Severe H7N9 Infection. [Abstract]

2019 Apr 7:2019:2121357. PMID: 31080811

SM-164 purchased from MedChemExpress. Usage Cited in: Biomed Res Int. 2019 Apr 7:2019:2121357. [Abstract]

The mouse alveolar epithelium cell line MLE12 is exposed to SM-164 for 24h with or without LPS for 24h. RIPK3 and MLKL are downregulated along with the inhibition of cIAP2 by SM-164 during LPS-induced ARDS.
Curr Protoc

Immunoprecipitation Strategies to Isolate RIPK1/RIPK3 Complexes in Mouse Macrophages. [Abstract]

2021 Jun;1(6):e156. PMID: 34106523
Res Sq

2025 Jul 20.
Res Sq

2025 Jul 16.
Patent

US20240294508A1.
Patent

US20240217963A1.
Georg Thieme Verlag KG
bioRxiv

2023 Aug 24.
Patent

US20230192662A1.
bioRxiv

2023 Apr 25.
Research Square Print

2022 May.

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (22.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.8917 mL

4.4586 mL

8.9173 mL

5 mM

0.1783 mL

0.8917 mL

1.7835 mL

10 mM

0.0892 mL

0.4459 mL

0.8917 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 0.83 mg/mL (0.74 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 0.83 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[2]

A set of sensitive and quantitative fluorescence polarization (FP)-based assays are developed to determine the binding affinities of our designed Smac mimetics to XIAP BIR3, XIAP containing both BIR2 and BIR3 domains, cIAP-1 BIR3, cIAP-1 containing both BIR2 and BIR3 domains, and cIAP-2 protein. The FP-based assay for XIAP BIR3 protein is measured. Briefly, 5-carboxyfluorescein is coupled to the lysine side chain of a mutated Smac peptide with the sequence (AbuRPFK-Fam) and this fluorescently tagged peptide (named SM5F) is used as the fluorescent tracer in FP-based binding assay to XIAP BIR3. The K_d value of this fluorescent tracer is determined to be 17.9 nM to XIAP BIR3. In competitive binding experiments, a tested compound is incubated with 30 nM of XIAP BIR3 protein and 5 nM of SM5F in the assay buffer (100 mM potassium phosphate, pH 7.5; 100μg/mL bovine gamma globulin; 0.02 % sodium azide)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

HCT116 colon cancer cells are treated with SM-164 (1, 10, and 100 nM) alone, TNFα alone, or the combination for 48 h. Cell growth inhibition is determined by a WST assay^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
SCID mice (8-10 per group) bearing MDA-MB-231 xenograft tumors are treated i.v. with 1 and 5 mg/kg of SM-164 or 7.5 mg/kg of Taxotere or vehicle control daily, 5 d/wk for 2 wk. Tumor sizes and animal weights are measured thrice a week^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94. [Content Brief]

[2]. Lu J, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15;68(22):9384-93. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.8917 mL	4.4586 mL	8.9173 mL	22.2932 mL
	5 mM	0.1783 mL	0.8917 mL	1.7835 mL	4.4586 mL
	10 mM	0.0892 mL	0.4459 mL	0.8917 mL	2.2293 mL
	15 mM	0.0594 mL	0.2972 mL	0.5945 mL	1.4862 mL
	20 mM	0.0446 mL	0.2229 mL	0.4459 mL	1.1147 mL

Keywords

SM-164

55 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

SM-164

Apoptosis Compound Library

Anti-Cancer Compound Library

Peptidomimetic Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) SM-164

Voir tous les produits spécifiques à Isoform IAP

Activité biologique

Chemical Information

Publications (55)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

SM-164

Apoptosis Compound Library

Anti-Cancer Compound Library

Peptidomimetic Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) SM-164

Voir tous les produits spécifiques à Isoform IAP

Activité biologique

Chemical Information

Publications (55)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

SM-164 Related Classifications

Cat. No.: HY-15989